Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,821 to 4,840 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Linagliptin 5 mg vs Placebo: serious adverse events | 87 of 631 83 of 630 | 0.6 points -3.2 to 4.4 | 1,261 | NCT00954447 Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Very Severe Hypoxemia | 15 of 624 36 of 637 | -3.2 points -5.5 to -1.1 | 1,261 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Hypoxemia | 57 of 624 118 of 637 | -9.4 points -13.2 to -5.6 | 1,261 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Severe Hypoxemia | 39 of 624 84 of 637 | -6.9 points -10.2 to -3.7 | 1,261 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): serious adverse events | 66 of 632 97 of 627 | -5.0 points -8.8 to -1.3 | 1,259 | NCT00946712 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
| LHRHa + TAK-700 vs LHRHa + Bicalutamide: serious adverse events | 235 of 627 15 of 629 | 35.1 points 31.1 to 39.1 | 1,256 | NCT01809691 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting High Confidence in Knowing BP Target Numbers at Six Months | 437 of 662 465 of 594 | -12.3 points -17.1 to -7.3 | 1,256 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Semaglutide vs Standard of Care: deaths from any cause | 9 of 634 9 of 621 | -0.0 points -1.5 to 1.4 | 1,255 | NCT03596450 Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial |
| Semaglutide vs Standard of Care: serious adverse events | 38 of 634 39 of 621 | -0.3 points -3.0 to 2.4 | 1,255 | NCT03596450 Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause | 507 of 624 499 of 629 | 1.9 points -2.5 to 6.3 | 1,253 | NCT02753127 A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer |
| Long Term Medication Assisted Treatment (LT-MAT) vs Short Term Medication Assisted Treatment (ST-MAT): serious adverse events | 38 of 623 42 of 628 | -0.6 points -3.3 to 2.2 | 1,251 | NCT00270257 Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users |
| Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 126 of 636 93 of 615 | 4.7 points 0.5 to 8.9 | 1,251 | NCT02220894 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) |
| Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Experienced At Least One Adverse Event (AE) | 608 of 636 606 of 615 | -2.9 points -4.9 to -1.1 | 1,251 | NCT02220894 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) |
| Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: deaths from any cause | 105 of 626 93 of 625 | 1.9 points -2.2 to 5.9 | 1,251 | NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) |
| PFC Sigma PS TKA (Total Knee Arthroplasty) vs PFC Sigma HP PS TKA (Total Knee Arthroplasty): serious adverse events | 45 of 625 29 of 625 | 2.6 points -0.1 to 5.2 | 1,250 | NCT01340144 Evaluation of Patellar Crepitus Following Total Knee Arthroplasty |
| GFRS EPD vs GEF EPD: Major Adverse Events (MAE) | 18 of 386 36 of 864 | 0.5 points -1.8 to 3.3 | 1,250 | NCT01343667 GORE Flow Reversal System and GORE Embolic Filter Extension Study |
| Telehealth Palliative Care: Patients vs In-person Palliative Care: Patients: deaths from any cause | 365 of 633 368 of 617 | -2.0 points -7.4 to 3.5 | 1,250 | NCT03375489 Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer |
| HIV Positive vs HIV Negative: High Risk (hr)-Human Papillomavirus (HPV) Positive Rate | 295 of 625 181 of 625 | 18.2 points 12.9 to 23.4 | 1,250 | NCT04092257 HPV-Based Screen-and-Treat Demonstration Project in Lilongwe |
| Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: serious adverse events | 252 of 625 145 of 625 | 17.1 points 12.0 to 22.1 | 1,250 | NCT04191096 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) |
| Dapagliflozin 10mg vs Placebo: Improving Clinical Recovery: Hierarchical Composite Outcome Measure Including Death From Any Cause Through Day 30, New/Worsened Organ Dysfunction, Clinical Status at Day 30 and Hospital Discharge Before Day 30 and Alive at Day 30. | 547 of 625 532 of 625 | 2.4 points -1.4 to 6.2 | 1,250 | NCT04350593 Dapagliflozin in Respiratory Failure in Patients With COVID-19 |
Code
curl "https://conductscience.org/api/comparisons/v1?page=242"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=242
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00954447-sae",
"title": "Linagliptin 5 mg vs Placebo: serious adverse events",
"summary": "87 of 631 against 83 of 630; risk difference 0.6 points, 95% interval -3.2 to 4.4; NCT00954447, Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes",
"record": "/library/comparisons/NCT00954447-sae",
"nct_id": "NCT00954447",
"kind": "serious-adverse-events",
"participants": 1261,
"risk_difference": {
"value": 0.006130354941765392,
"lower": -0.031713044080248616,
"upper": 0.04397310913567905
},
"group_1": "87 of 631",
"group_2": "83 of 630",
"difference": "0.6 points",
"interval": "-3.2 to 4.4",
"trial_title": "Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes"
},
{
"id": "NCT05267652-1bd84381",
"title": "Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Very Severe Hypoxemia",
"summary": "15 of 624 against 36 of 637; risk difference -3.2 points, 95% interval -5.5 to -1.1; NCT05267652, Pragmatic Trial Examining Oxygenation Prior to Intubation",
"record": "/library/comparisons/NCT05267652-1bd84381",
"nct_id": "NCT05267652",
"kind": "outcome",
"participants": 1261,
"risk_difference": {
"value": -0.03247645211930926,
"lower": -0.05524824227990783,
"upper": -0.010797422640163156
},
"group_1": "15 of 624",
"group_2": "36 of 637",
"difference": "-3.2 points",
"interval": "-5.5 to -1.1",
"trial_title": "Pragmatic Trial Examining Oxygenation Prior to Intubation"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=243",
"request_id": "5NZfF8xlvCYte_J8"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant